IVF success could double with new way of detecting faulty egg cells

Whole-genome sequencing allows doctors to detect both genetic mutations associated with inherited disorders and chromosomal abnormalities in egg cells before fertilization. By identifying and selecting only genetically normal eggs for IVF, embryos with genetic problems can be avoided, significantly increasing the likelihood of a successful pregnancy and healthy baby. This comprehensive screening in a single analysis reduces the need for multiple testing procedures.

While the research shows promising results, this specific whole-genome sequencing method for egg cells is still in the research phase and is not yet widely available through standard FDA-approved fertility clinics in the US. Fertility patients should consult with their reproductive endocrinologist or clinic about current preimplantation genetic testing (PGT) options available, as the American Society for Reproductive Medicine (ASRM) continues to evaluate emerging technologies.

Traditional PGT typically screens embryos after fertilization for specific genetic disorders (PGT-M) or chromosome abnormalities (PGT-A), whereas this new approach performs whole-genome sequencing on unfertilized egg cells before they are fertilized. By identifying problems at the egg stage rather than the embryo stage, this method could potentially be faster, more cost-effective, and eliminate the need to create and then discard abnormal embryos, aligning with the preferences of some patients.

Coverage for genetic screening tests varies significantly by insurance plan and state regulations in the US. Most traditional fertility treatments and PGT are not fully covered by standard insurance plans, though some policies offer partial coverage. Once this technology becomes commercially available, patients should contact their insurance provider directly to determine coverage eligibility and out-of-pocket costs.

This screening would occur before fertilization takes place, as it analyzes individual egg cells

during the egg retrieval phase of an IVF cycle. This differs from embryo-based genetic testing (PGT), which is performed 5-7 days after fertilization when the embryo reaches the blastocyst stage. Early screening at the egg stage could streamline the IVF process and potentially reduce the number of steps before embryo transfer.

Pricing has not yet been established for this research-based technology in the US market. Current preimplantation genetic testing (PGT) typically costs $2,000-$5,000 per cycle at American fertility clinics. Once this whole-genome sequencing method becomes commercially available, costs will depend on the clinic, location, and whether insurance provides any coverage.

Yes, this method is particularly relevant for age-related fertility issues, as chromosome abnormalities in eggs increase significantly with maternal age. By detecting aneuploidies (abnormal chromosome numbers) before fertilization, women over 35—who have higher rates of chromosomal problems—could benefit substantially from this screening technology. This could potentially improve success rates for older women pursuing IVF, which is currently a significant challenge in reproductive medicine.